Development StagesAll of GBIO's programs are at early stages of development and will require substantial work to achieve clinical proof of concept.
Offer Price ConcernsThe offer price of $4.29 per share is below GBIO's pre-deal price of approximately $5.4 per share.
Strategic AlternativesGeneration Bio has been pursuing strategic alternatives including but not limited to potential M&A, partnerships, or asset sales.